PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009[update].
^Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov